arznei-telegramm Logo a-t Kurzlogo
    ❮ a-t 7/2013 a-t ❯
    This is a translation of the table of contents. One article of each issue is translated and freely available.
    table of contents
    SPOT ON

    Rivaroxaban (XARELTO) now also approved for acute coronary syndrome

    NEW ON THE MARKET

    Linaclotide (CONSTELLA) for irritable bowel syndrome with constipation

    THERAPY FROM A CRITICAL VIEWPOINT

    Rheumatoid arthritis: biological versus classic DMARDs

    a-t READERS' QUESTIONS AND COMMENTS

    Shortened antibiotic treatment due to rebate contract?

    URO-VAXOM against recurrent urinary tract infection?

    IN BRIEF

    First endpoint study with an incretin-based antidiabetic is negative

    Now official: no codeine for children

    Bone growth factor dibotermin alfa (INDUCTOS, INFUSE) - paid opinion leaders, ghostwriting, data manipulation and insufficient evidence of benefit

    Medical sales representatives without control

    Hydroxyl ethyl starch shall be withdrawn from the market

    CURRENT ADR NETWORK REPORT

    Renal failure with gyrase inhibitors

    SIDE EFFECTS

    The Federal Institute for Drugs and Medical Devices (BfArM) and FUMADERM (dimethyl fumarate and monoethyl fumarates): poor risk management
    free

    Finally: restrictions in the use of flupirtine (KATADOLON, generics)

    e a-t IN INTERNET

    MUTAFLOR (E. coli Nissle) against sun allergy?

    arznei-telegramm

    Independent drug information – in English

    Concise, critical evaluations of drugs and medical devices for evidence-based therapy and patient advice on benefits and risks – independent, ad-free and funded exclusively by subscriptions.

    Browse free articles